Masimo (NASDAQ:MASI) Price Target Raised to $166.00 at BTIG Research

Masimo (NASDAQ:MASIFree Report) had its target price increased by BTIG Research from $145.00 to $166.00 in a research note published on Monday morning, Benzinga reports. The firm currently has a buy rating on the medical equipment provider’s stock.

A number of other analysts also recently weighed in on MASI. Wells Fargo & Company upgraded Masimo from an equal weight rating to an overweight rating and increased their price target for the stock from $117.00 to $160.00 in a report on Monday. Jefferies Financial Group reiterated a hold rating and set a $121.00 price target (up from $107.00) on shares of Masimo in a report on Tuesday, January 30th. Piper Sandler increased their price target on Masimo from $70.00 to $117.00 and gave the stock a neutral rating in a report on Monday, February 26th. Needham & Company LLC cut shares of Masimo from a buy rating to a hold rating in a research report on Wednesday, January 3rd. Finally, cut shares of Masimo from a hold rating to a sell rating in a research report on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of Hold and an average target price of $134.29.

Check Out Our Latest Stock Report on Masimo

Masimo Stock Up 3.3 %

Shares of NASDAQ:MASI opened at $139.43 on Monday. The company has a fifty day moving average of $130.91 and a 200-day moving average of $108.77. The company has a market capitalization of $7.38 billion, a PE ratio of 92.34 and a beta of 0.95. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18. Masimo has a 52-week low of $75.22 and a 52-week high of $198.00.

Masimo (NASDAQ:MASIGet Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.43. The business had revenue of $548.90 million during the quarter, compared to the consensus estimate of $545.69 million. Masimo had a return on equity of 13.77% and a net margin of 3.98%. Masimo’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.32 earnings per share. On average, equities analysts predict that Masimo will post 3.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Masimo

Several institutional investors have recently bought and sold shares of MASI. Caisse DE Depot ET Placement DU Quebec purchased a new stake in Masimo in the 1st quarter worth approximately $37,000. Byrne Asset Management LLC purchased a new position in shares of Masimo in the 4th quarter valued at approximately $28,000. Massmutual Trust Co. FSB ADV raised its holdings in Masimo by 140.6% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Masimo by 851.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 264 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Masimo in the 4th quarter worth about $36,000. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

About Masimo

(Get Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Featured Stories

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with's FREE daily email newsletter.